Ocuphire Pharma Investor Day Presentation Deck

9 Phase 1, Phase 2, and Phase 3 Trials 7 Nyxol & APX3330: Drug Development History and Patents Significant Preclinical & Clinical Data Supporting Human Safety, MOA, Efficacy, and PK Refractivel Retina P >330 Subjects Dosed Presbyopia NyxolⓇ Novel a1/ a2 Blocker 505(b)(2) Source: Eisai and Apexian Data Exposure in Humans 28 Days Night Vision Disturbances Reversal of Mydriasis Patent Coverage 2034+ NVD RM 11 Phase 1 & Phase 2 Trials DR APX3330 Oral REF-1 Inhibitor New Chemical Entity >340 Subjects Dosed Exposure in Humans 365 Days Patents to 2034+ Diabetic Retinopathy Diabetic Macular Edema DME Ocuphire PHARMA

View entire presentation